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Abstract
Hyperparathyroidism jaw tumour syndrome is a rare autoso-
mal dominant inherited endocrine neoplasia syndrome, which
predisposes carriers to develop a triad of multiple ossifying
fibromas of the maxilla and mandible, parathyroid adenomas
and carcinomas (with consequent hyperparathyroidism) as
well as renal and uterine tumours. The prevalence of this con-
dition is unknown. Patients typically present initially with
symptoms and signs of a jaw tumour. A high index of suspi-
cion is required for the underlying diagnosis to be recognised,
enabling appropriate management of jaw lesions, treatment of
hyperparathyroidism, if present, as well as early detection of
malignant disease and screening of family members.
Teaching points
• HPT-JT is a rare autosomal dominant inherited endocrine
neoplasia syndrome.
• HPT-JT causes facial disfigurement, morbidity secondary to
hyperparathyroidism and malignancy.
• Patients can present with ossifying fibromas of the jaw,
hypercalcaemia or malignancy.
• A high index of suspicion is required for the underlying
diagnosis to be recognised.
• Management involves screening of family members.
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Introduction
Hyperparathyroidism jaw tumour syndrome (HPT-JT) is a
rare autosomal dominant inherited endocrine neoplasia syn-
drome, which predisposes carriers to develop a triad of multi-
ple ossifying fibromas of the maxilla and mandible, parathy-
roid adenomas and carcinomas (with consequent hyperpara-
thyroidism), as well as renal and uterine tumours.
Genetics
HPT-JT is inherited in an autosomal dominant pattern and can
demonstrate incomplete penetrance. Instances of sporadic mu-
tations arising de novo have been recorded [1]. The syndrome
arises from a gene mutation, which inhibits the production of
normal parafibromin, a protein that regulates cell proliferation
and can arrest the cell cycle [1]. The gene responsible for
parafibromin expression is the HRPT2 tumour suppressor
gene (also known as the CDC73 gene), which has been local-
ised to a 34-cM region on 1q25 - q31 [2]. Mutations of
HRPT2 are identified in most individuals affected by HPT-
JT (and many of their asymptomatic family members) [3].
Loss of normal parafibromin expression allows certain tissues
to propagate unimpeded. Gene sequencing is of use in
confirming the diagnosis and differentiating the disease from
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other inherited endocrine neoplasia syndromes which also
have parathyroid manifestations (e.g., multiple endocrine neo-
plasia (MEN) types I and II).
Clinical presentation
Individuals with HPT-JT typically present with jaw and
teeth deformities secondary to ossifying fibromas of the
maxilla and mandible. These produce a hard, deforming
jaw swelling, which can cause early tooth displacement.
Alternatively, they may present with symptoms and signs
of hypercalcaemia secondary to hyperparathyroidism due
to an underlying parathyroid adenoma or carcinoma. A
few patients will also be detected incidentally with a high
serum calcium on blood biochemistry that subsequently
prompts further investigation. Unfortunately, some pa-




Ossifying fibromas of the jaw are a type of benign
fibro-osseous lesion detected in approximately 50 % of
HPT-JT individuals and present in adolescents or young
adults [2]. In contrast, sporadic ossifying fibromas of the
jaw are rare and typically occur in an older age group [4].
Ossifying fibromas of the jaw arise from the mesenchymal
cells of the periodontal ligament, the fibrous connective
tissue found within the periodontal space, which secures
the tooth [5]. They are composed of fibrous tissue with
varying amounts of mature bone, osteoid and cementum
[6] .
On plain film and CTossifying fibromas appear as well-
circumscribed expansile lesions arising within the mandible
ormaxilla (Fig. 1). They are commonly uniocular, but canbe
multilocular and demonstrate sizeable growth (greater than
10cm)[5].Onplain film imaging, theyareusually lucent,but
can demonstrate a mixed opacity or be completely radio-
opaque, depending on the relative fibrous and calcified com-
ponents [7]. They typically have a sclerotic rim. On CT they
demonstrate internal soft tissue density, which reflects the
fibrous component (Fig. 2). On MR T1-weighted imaging
they return low to intermediate signal, the low signal areas
reflecting theosseous component.OnT2-weighted imaging,
they contain a mixture of low and high signal components
reflecting the osseous and fibrous components, respectively
[6]. The fibrous component of the tumour enhances follow-
ing administration of contrast [6]. Ossifying fibromas typi-
cally do not cause root absorption,which is a feature ofmore
aggressive lesions such as ameloblastomas, andunlike radic-
ular or dentigerous cysts, there is no association with
unerupted teeth [4].
Fig. 1 An orthopantomogram of an 18-year-old female that demon-
strates an ossifying fibroma of the right body of themandible. The solitary
expansile lesion splays the teeth and has a discernible sclerotic rim, but no
destructive features, e.g., root resorption
Fig. 2 a), b) Axial 1.5 mm CT images through the mandible of a 30-
year-old female with HPT-JT. There are multiple bilateral ossifying
fibromas of the mandible, as is typical of the condition. Ossifying
fibromas are composed of fibrous tissue with varying amounts of
mature bone, and; therefore, as demonstrated here, some lesions are
purely lucent, while others will have a more conspicuous calcified
component
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Ossifying fibromas of the jaw are benign lesions with the
risk of malignant degeneration being less than <0.5 % [5].
However, they demonstrate locally invasive features, e.g.,
theymaysplay the teeth [4].Theyareexpansileandcancause
facial asymmetry. They can extend into the maxillary sinus
(Fig. 3). Extension into the orbital floor may precipitate
periorbital swelling, orbital pain or changes in visual acuity
(Fig. 4). If left untreated, ossifying fibromasmay continue to
enlarge and become severely disfiguring (Fig. 5).
The distinction from fibrous dysplasia and osteolytic
Brown tumours of hyperparathyroidism is an important one
asbothconditionsmayalsoarise in the jaw.Fibrousdysplasia
produces ill-defined bony expansion and has a characteristic
‘ground glass’ appearance, but it can be indistinguishable
from an ossifying fibroma on imaging (Fig. 6) underlining
the importance of multidisciplinary team discussion in mak-
ing the diagnosis of an ossifying fibroma, and the need to
review and correlate clinical, imaging and histopathological
evidence [4]. As with ossifying fibromas of HPT-JT, Brown
tumours may also appear on imaging as lucent jaw lesions
with evidence of hyperparathyroid bone disease in the sur-
roundingbone [7].However,Brown tumours arepurely lytic
lesions,which lack thesclerotic rimassociatedwithossifying
fibromas. Other important differentials are cementomas,
which appear uniformlydensewhenmature, andosteosarco-
mas, which appear as ill-defined destructive lesions charac-
terized by aggressive periosteal reaction [6].
ii. Parathyroid adenomas and carcinomas
HPT-JT patients with parathyroid adenomas or carci-
nomas will develop primary hyperparathyroidism and
consequent hypercalcaemia. Patients may present with
typical but non-specific symptoms of hypercalcaemia in-
cluding malaise, depression, renal stones and abdominal
pain or incidentally identified following identification of a
raised serum calcium on blood biochemistry.
Hyperparathyroid bone disease is characterised by
subperiosteal bone resorption, sclerotic bone changes
and/or terminal tuft reabsorption (Fig. 7) [8]. The
Fig. 3 a) Axial and b) coronal CT images with c) TI-weighted axialMRI
at the level of the maxillary sinuses in a 60-yr-old male with HPT-JT. The
patient presented with symptoms of chronic sinusitis and CT imaging
demonstrates an ossifying fibroma which arises from the maxilla and
almost obliterates the left maxillary sinus. On MR the imaging features
are those of a partially ossified expansile fatty soft tissue mass, areas of
focal low signal on the T1weighted sequence reflect the calcified osseous
components of the ossifying fibroma. There is evidence of previous
sinonasal surgery with wide bilateral medial antrostomies, middle
turbinectomies, uncinectomies and ethmoidectomies. Opacification, sug-
gestive of a mucocele, was noted in the anterior ethmoid and frontal
sinuses
Fig. 4 a) Coronal T2-weighted and b) axial post-contrast T1 fat-
saturated MR images. The patient from Fig. 3 subsequently represented
two years later with difficulty opening his right eye and changes in visual
acuity. MRI demonstrated an enhancing mass lesion centered on the
ethmoid sinuses, naso ethmoid complex and cribiform plate, which
invades both orbits. There is invasion of the intraconal space of the right
orbit, displacement of the right optic nerve and inferior lateral displace-
ment of the right globe. The lesion was proven on biopsy to be an ossi-
fying fibroma, although it behaved atypically in an invasive manner
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presence of jaw lesions in combination with bone changes
suggestive of hyperparathyroid bone disease should
prompt the radiologist to consider HPT-JT and review
for a parathyroid lesion (Fig. 8).
In HPT-JT, parathyroid adenomas develop in a younger
population with a mean age of diagnosis at 33 years, and
there is a propensity for them to reoccur following removal
as well as developing new adenomas [2]. In contrast, spo-
radic parathyroid adenomas typically occur as solitary single
episode tumours beyond 40 years of age, with a predilection
for the female population [9]. HPT-JT individuals are at a
higher risk of developing parathyroid carcinoma, a rare ma-
lignancy in the general population [10].
Parathyroid adenomas and carcinomas appear as solitary
solid soft tissue masses the majority of which are
juxtathyroid and located immediately posterior or inferior
to the thyroid gland, although they can be located as inferior
as the mediastinum [11]. First line assessment to identify
parathyroid gland enlargement varies between institutions,
but is typically performed with a combination of ultrasound
and nuclear medicine scintigraphy. On ultrasound, parathy-
roid adenomas and carcinomas are uniformly hypoechoic
and often demonstrate increased vascularity with identifica-
tion of a vascular pedicle (Fig. 9) [11]. Nuclear medicine
Fig. 5 a) Midline sagittal CT image b) axial CT image at the level of
maxilla with c) CT 3-D soft tissue volume rendered image and d) sagittal
CT tomogram of a 19-yr-old female from an east African country. This
case illustrates how deforming HPT-JT can become in an environment
with poor access to healthcare resources. This patient’s underlying diag-
nosis was not made prior to her presentation in the UK for debulking
surgery. There are extensive ossifying fibromas affecting the entire cra-
niofacial skeleton causing considerable disfigurement of the facial
features, encroaching on the orbits and compromising her airway to the
extent that she required a tracheostomy. There is evidence of previous
surgical intervention in the form of a right jaw strut. e) Axial CT through
the upper thorax. On her initial CT incidental note was made of an en-
hancing ovoid lesion in the right paratracheal recess (arrowhead), the
underlying diagnosis of HPT-JT was suggested by the radiologist, and
this lesion was subsequently proven to be a parathyroid adenoma
Fig. 6 Axial 1.5 mm CT bone reformats of mandible. There is wide
variation in the imaging appearances of ossifying fibromas, often the
diagnosis of lucent jaw lesions will only be made following MDT
discussion and histopathology sampling. This ossifying fibroma of the
right body of the mandible demonstrates the internal ground glass texture
more commonly associated with fibrous dysplasia, which, along with
Browns tumours, are important differentials for a suspected ossifying
fibroma
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Fig. 7 a) Axial CT bone reformat
through skull base b) coronal CT
bone reformat of left mandible in
a 50-year-old male with HPT-JT
and extensive hyperparathyroid
bone disease. There is a ‘salt and
pepper’ appearance to the skull
base secondary to trabecular bone
reabsorption. Subperiosteal bone
reabsorption of the lamina dura
gives a floating appearance to a
left lower molar tooth (b). There
has been substantial maxillary
bone loss and loss of the upper left
dentition
Fig. 8 a) Sagittal oblique CT and b) axial CT image of the skull
base c) axial CT upper thorax. 34-yr-old female with undiagnosed
HPT-JT who underwent a CT to assess a left mandibular ramus
lesion (a) subsequently proven to be an ossifying fibroma. She
was incidentally noted to have generalised bony sclerosis (b) sug-
gestive of hyperparathyroid bone disease and further imaging (c)
revealed a retrosternal parathyroid adenoma (arrowhead) anterior
to the left brachiocephalic vein
Fig. 9 a) Longitudinal ultrasound image of a parathyroid adenoma in a 54-yr-old female with HPT-JT. The adenoma (arrowhead) corresponds to the
elongated hypoechoic structure caudal to the thyroid. On application of colour Doppler (b) the lesion is demonstrated to be hypervascular
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Fig. 10 A nuclear medicine parathyroid scintigraphy study (image
courtesy of Dr Cindy Leung, Barts and The London). The
Technetium pertechnetate (99mTc-pertechnetate) image (upper
row, far left) demonstrates localization of the thyroid gland.
99mTc-Sestamibi (MIBI) images show a focal area of significant
increased tracer uptake inferior to the left thyroid lobe, which
persists on early (centre and far right, upper row) and delayed
imaging (centre and far right, lower row). Imaging characteristics
are consistent with a parathyroid adenoma. Tracer uptake else-
where is physiological
Fig. 11 a) Transverse ultrasound image of thyroid and b) coronal
FDG PET-CT of the thorax of a 50-year-old male with HPT-JT
who has a parathyroid carcinoma and a bone metastasis at pre-
sentation. The ultrasound (a) demonstrates a hypoechoic parathy-
roid neoplasm (arrowhead) indenting the thyroid with findings
suspicious for underlying invasion of the prever tebral
musculature. The PET-CT demonstrates intense tracer uptake in
the left posterior T8 vertebral body, which was proven on biopsy
to be a metastatic deposit. Focal uptake in the left 7th rib is
secondary to a rib fracture. HPT-JT patients have a greater pre-
disposition to develop parathyroid carcinomas than the general
population
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‘wash out’ scinitigraphy using Technetium 99 m Sestamibi
tracer is the ‘gold standard’ for the detection of parathyroid
adenoma [12]. The tracer is retained within parathyroid ad-
enoma and carcinomas and demonstrates increased uptake
on both early and late imaging (Fig. 10). In contrast, there is
rapidwash out of tracer from the adjacent thyroid gland [13].
CT and MRI are employed when there is non-concordance
between first line imaging investigations and in patients who
have typically undergone previous surgical intervention to
remove a parathyroid adenoma/carcinoma [11]. Selective




adenomas; however, the imaging appearances can be indis-
tinguishable although parathyroid carcinomas are typically
larger andmay demonstrate invasive features, e.g., invasion
of the prevertebral muscles and surrounding structures
(Fig. 11) [14]. Therefore, in the absence of obviousmetasta-
tic disease, the diagnosis is typically confirmed following
surgical resection.
iii. Renal and uterine tumours
Wilms tumours,nephroblastomas,harmatomas,papillary
renal cell carcinomas and an increased incidence of simple
renal cysts have been reported in HPT-JT patients [15–17].
There is a reported higher incidence of uterine carcinomas
and uterine polyposis in femaleswithHPT-JT [17].
Management
The management of ossifying fibromas in HPT-JT comprises
complete surgical excision of jaw lesions with bone grafting
and reconstruction. Patients with parathyroid lesions on imaging
will often undergo a subtotal parathyroidectomy or total parathy-
roidectomywith autotransplatation [10]. The decision to perform
total parathyroidectomy is based on consideration of the hor-
mone levels and severity of parathyroid bone disease. HPT-JT
individuals should be managed with a medical surveillance plan
[10]. Plain film or CT can be used to detect jaw lesions, serum
calcium measurements to detect parathyroid lesions and a com-
bination of ultrasound and MRI can be used to evaluate the
kidneys and uterus. Currently, there is no standardized manage-
ment plan. Finally, family members can be screened genetically
for the condition.
Conclusion
HPT-JT is a rare syndrome with a significant potential for the
development of facial disfigurement, morbidity secondary to hy-
perparathyroidism and malignancy. This topic is important for
radiologists because patients will often first present with
ossifying fibromas of the jaw. A high index of suspicion is re-
quired for the underlying diagnosis to be recognised, enabling
treatment of hyperparathyroidism, early detection of malignant
disease and screening of family members. Recurrent or multiple
jaw lesions or the combination of jaw lesions and
hyperparathyroid bone disease on imaging should raise the pos-
sibility of HPT-JT.
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